It covers the computational systems that we built to design and test a new family of chemical compounds in silico, synthesis of several prototypes, all the way through preliminary in vivo testing. It’s the culmination of about 4 yrs of work starting at SENS, finished at Underdog and involving collaborations with leading experts in Spain, Hungary, and China. Give it a look and let us know what you think!
Watch Cyclarity CEO of Scientific Affairs Dr. Oki O’Connor talk with Phil Newman of Longevity.Technology about Cyclarity’s elegant solution to one of the world’s biggest problems – atherosclerosis.
Congratulations to our diligent and talented team members who are taking on larger roles as we develop our novel technologies to cure atherosclerosis!
We invite you to read the Longevity.Technology report “Disease management to disease modification – removing plaque to undo atherosclerosis”.
Watch Cyclarity CEO of Corporate Affairs Mike Kope talk with Phil Newman of Longevity.Technology about tackling oxidized cholesterol and taking on the world’s biggest killer.
Watch Cyclarity’s CEO of Corporate Affairs Mike Kope discuss company strategy and the work to prevent age-related conditions such as atherosclerosis, heart attack, and stroke by addressing the root cause at the Rejuvenation Startup Summit 2022.
Press Release Novato, CA, U.S., June 24, 2022 – Announcing our move to the Buck Institute for Research on Aging. Cyclarity Therapeutics (https://cyclaritytx.com) has just completed the move of its research and operations to the state-of-the-art
Press Release Novato, CA, U.S., June 24, 2022 – Announcing our corporate name change and new branding. We’re excited to announce that Underdog Pharmaceuticals has changed its name to Cyclarity Therapeutics. We remain exactly on
KIZOO Technology Capital owner Michael Greve discusses the recent scientific advancements in addressing the root causes of age-related diseases in the rejuvenation biotechnology sphere—including the work of Underdog Pharmaceuticals. As one of Kizoo’s key startups, Underdog’s goal is to deliver affordable therapeutics for the prevention of heart disease and stroke through the removal of arterial plaque.
Underdog Pharmaceuticals, a key investment of Michael Greve’s rejuvenation biotech VC Kizoo, has closed a $10 million round of capital. Kizoo led the company’s Series Seed II round, which saw participation from both existing and new investors.
Underdog was recently awarded the Innovation Passport under the United Kingdom’s Innovative Licensing and Access Pathway (ILAP). This will enable faster patient access to its groundbreaking treatment for the prevention of heart attacks and stroke. The company expects to begin clinical trials in 2023.
Press Release Mountain View, CA, U.S., September 8, 2021 –Underdog Pharmaceuticals, Inc. (Underdog), a pre-clinical stage pharmaceutical company focusing on the treatment and reversal of age-related diseases, has been awarded an Innovation Passport under the
Underdog Pharmaceuticals, Inc., a pharmaceutical company designing engineered cyclodextrins to address atherosclerosis and other serious diseases of aging, has concluded a successful meeting with the Medicines and Health products Regulatory Agency (MHRA) of the UK.
Kizoo Technology Capital GmbH has recently announced a $362M commitment to invest in rejuvenation biotechnology. If you haven’t seen the compelling write-up in BioWorld Today, please take a moment to read it here. Underdog was
